Cost-benefit analysis of bone marrow (BM) immunophenotyping (IP) in the staging of non-Hodgkin's lymphoma (NHL) (Meeting abstract). NLM AIDSLINE Important note: Information in this article was accurate in 1994. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


Cost-benefit analysis of bone marrow (BM) immunophenotyping (IP) in the staging of non-Hodgkin's lymphoma (NHL) (Meeting abstract).

Proc Annu Meet Am Soc Clin Oncol; 13:A1332 1994. Unique Identifier : AIDSLINE ICDB/94601328
Denes AE; Hathaway C; St. John's Mercy Medical Center, St. Louis, MO 63141

Abstract: BM IP is often used in conjunction with light microscopy (LM) in the staging evaluation of patients (pts) with NHL. We conducted a retrospective review of 50 BM staging procedures to determine the sensitivity of IP in the detection of occult BM involvement in pts with NHL. IP was performed on an Epics II Profile flow cytometer (Coulter) using a panel of 6-15 antibodies (n=10). Pts ranged in age from 20-86 yr and the male:female ratio was 23:27. Results are summarized in a table. In only one pt was a clonal proliferation detected by IP that was not apparent by LM. This was a B cell lymphoproliferative disorder in an HIV+ pt with fever and diffuse adenopathy. The total cost of IP in these 50 pts was 49,824 dollars (range 576-1344 dollars, m=996 dollars/pt sample). These results indicate that IP is not more sensitive than LM in the detection of BM involvement by NHL. The routine use of BM IP in the staging evaluation of pts with NHL is not recommended.
Keywords: Adult Aged Aged, 80 and over Bone Marrow/*PATHOLOGY Cost-Benefit Analysis Female Human Immunophenotyping/*ECONOMICS Lymphoma, Non-Hodgkin's/ECONOMICS/*PATHOLOGY Male Middle Age Neoplasm Staging Retrospective Studies ABSTRACT

KWDadultagedaged,80andoverbonemarrow/KWDpathologycost-benefitanalysisfemalehumanimmunophenotyping/KWDeconomicslymphoma,non-hodgkin's/economics/KWDpathologymalemiddleageneoplasmstagingretrospectivestudiesabstract
940930
M9491046

Copyright © 1994 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1994. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1994. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .